Immunome, Inc.

Equities

IMNM

US45257U1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-23 EDT			5-day change	1st Jan Change
14.34 ^USD	-0.55%		-3.11%	+34.02%

05-21	Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing	MT
05-20	Immunome Completes Purchase of Antibodies From Atreca	MT

Immunome, Inc. Appoints Diane Marcou as Interim Chief Financial Officer

December 04, 2020 at 06:05 am

Effective on November 30, 2020, Immunome, Inc. appointed Diane Marcou as Interim Chief Financial Officer of the Company. Ms. Marcou previously served as the Company's Chief Financial Officer from May 2020 through September 2020.

Latest news about Immunome, Inc.

Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing	05-21	MT
Immunome Completes Purchase of Antibodies From Atreca	05-20	MT
Immunome, Inc. completed the acquisition of Substantially all Assets of Atreca, Inc..	05-19	CI
Immunome Appoints Max Rosett as CFO	05-17	MT
Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer	05-17	CI
Immunome, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	05-13	CI
Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	05-13	CI
Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	05-13	CI
Immunome, Inc. Appoints Kinney Horn as Chief Business Officer	05-02	CI
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target	04-30	MT
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	04-25	CI
Guggenheim Starts Immunome With Buy Rating, $35 Price Target	04-15	MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating	04-01	MT
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	03-24	CI
Immunome Closes $230 Million Public Offering	02-16	MT
Immunome Prices Stock Offering at $20 a Share	02-14	MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating	02-07	MT
Sector Update: Health Care Stocks Gain Late Afternoon	02-06	MT
Top Midday Gainers	02-06	MT
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	02-06	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	02-05	CI
Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations	02-01	CI
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	01-23	MT

Chart Immunome, Inc.

Duration

Period

More charts

Company Profile

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Immunome, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.42 USD

Average target price

32.5 USD

Spread / Average Target

+125.38%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNOME, INC.	+34.02%	864M
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	115B
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B
BIONTECH SE	-6.20%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.41%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.84%	12.13B

Bio Therapeutic Drugs